Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure

BACKGROUND: Nivolumab and regorafenib are approved second-line therapies for patients with hepatocellular carcinoma (HCC) after sorafenib failure. This study compared the effectiveness of nivolumab and regorafenib following sorafenib. METHODS: We retrospectively enrolled HCC patients who had undergo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Kuo, Yuan-Hung, Yen, Yi-Hao, Chen, Yen-Yang, Kee, Kwong-Ming, Hung, Chao-Hung, Lu, Sheng-Nan, Hu, Tsung-Hui, Chen, Chien-Hung, Wang, Jing-Houng
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8201513/
https://ncbi.nlm.nih.gov/pubmed/34136408
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.683341
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados